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Abstract
Background: Stroke is a major cause of morbidity and mortality worldwide. Neuropsychiatric disorders are often associated with stroke and, among them, 
depression is the most prevalent. Post-stroke Depression (PSD) is related to disability, failure in returning to work, impairment in interpersonal functioning 
and mortality. Its etiopathogenesis is still uncertain, as well as its treatment. In Brazil, there are few data on the impact of PSD. Objective: This work is dedica-
ted to conduct a comprehensive review of the concept of PSD, its pathophysiology, morbidity and treatment. Methods: PubMed, Medline and Lilacs searches 
of relevant terms yielded 3,265 papers in the last 10 years. We selected original studies and reviews that addressed the aspects mentioned above. Results: We 
present the history of the notion of PSD and describe its epidemiology, looking to highlight Brazilian studies. Diagnostic criteria and clinical presentation 
were detailed, with emphasis on cognitive aspects. The four main pathophysiological theories proposed to PSD are presented and we discuss the various tre-
atment strategies, involving psychopharmacologic options, brain stimulation techniques and psychotherapy. Discussion: This work provides comprehensive 
information on PSD, of great utility for clinical practice and research in this topic.
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Introduction
Stroke is a major cause of death and disability worldwide1. In the 
United States (US), there are approximately 610,000 new cases each 
year1. In Brazil, epidemiologic data are scarce. The available infor-
mation allows stating that stroke is the main cause of death in the 
country, accounting for approximately 100,000 deaths annually2. 
Nevertheless, over the last decades there has been a global trend of 
decrease in stroke mortality. This is probably due to the improvement 
in acute stroke management and to preventive measures, such as 
arterial hypertension treatment. In Brazil, there is also a decrease in 
stroke mortality, but restricted to the South and Southeast regions2. 
Currently, an estimated 5 million stroke survivors live in the US1. 
In Brazil, where the highest stroke death rates in Latin America are 
found, it is estimated that stroke survivors achieve at least half of 
that sum2. As the management of acute stroke continues to improve, 
the number of survivors will increase even more and, since it often 
results in major changes in the patient’s life, factors associated with 
morbidity have received increased attention.
Stroke is frequently associated with psychiatric symptoms such 
as depressed mood, anxiety and apathy3. The psychiatric complica-
tions of stroke, although recognized for more than one century, have 
never received the attention that has been devoted to other stroke 
complications, such as motor impairment, language problems, or 
cognitive deficits4.
Depression is the most common neuropsychiatric condition 
experienced after stroke4. More than a hundred years ago, Adolf 
Meyer postulated that depression should be the consequence of the 
combined effects of brain injury, affecting mainly the left frontal 
lobe as well as other lobar convexities, and psychosocial vulner-
ability, such as past psychiatric history. In the beginning of the XX 
century, Eugen Bleuler noted that after stroke “melancholic moods 
lasting for months and sometimes longer appear frequently”. Further 
in this direction, in 1962, after assessing 100 elderly patients with 
depression, Post remarked that the association of brain ischemia 
with a first episode of depressive disorder was so common that the 
causes of atherosclerotic disease and depression should be “etiologi-
cally linked”. However, although the association of depression with 
stroke has been clinically recognized for several decades, only in the 
past 25 years systematic studies have been conducted, with emerging 
evidence that depression after a stroke is associated with increased 
disability, increased cognitive impairment and, ultimately, worse 
rehabilitation outcomes and increased mortality3,4.
This review aimed to gather information on available epide-
miological, pathophysiological, clinical and therapeutic aspects of 
post-stroke depression (PSD), their impacts in patient’s recovery 
and, when possible, to contextualize them to the Brazilian scenario.
Methods
We conducted a narrative review of the literature through Lilacs, 
Medline and PubMed electronic databases, using the keywords 
“stroke”, “cerebrovascular diseases”, “depression” and “post-stroke 
depression”. When indicated, other bibliographies were consulted 
from the reference lists of these articles. The search was restricted 
to articles published in English and Portuguese, in the last ten years. 
After this step, the titles and abstracts of all articles found were read 
in order to identify studies that addressed the theme and purpose 
of this review.
Results
Historical perspective
Isolated studies with patients affected by PSD started to appear in 
the 1960s4. Most of these works adopted a perspective of “empathic 
understanding”. In other words, these researchers explained PSD as 
a natural and understandable emotional reaction of the individual 
to a decrease in self-esteem produced by the combination of a life-
threatening injury, the associated physical and intellectual disability, 
and the resulting loss of independence. Adopting such psychological 
perspective, Guido Gainotti’s group, from the Catholic University of 
Rome, Italy, conducted the first systematic study of neuropsychiatric 
symptoms in patients with stroke or other brain injuries4. His works 
can be considered one of the main representatives of the idea that 
the depressive syndromes associated with stroke may not be “true” 
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depressions, but a completely different category from Major Depres-
sive Disorder (MDD) that would be associated with the patients’ 
adjustment to changes in their living conditions14.
In 1977, however, Folstein et al. conducted a study comparing the 
prevalence of mood disorders in patients with stroke or orthopedic 
problems which all presented comparable functional disability5. They 
observed that patients with stroke exhibited a far greater frequency 
of depression than orthopedic patients, and concluded that mood 
disorders would be a complication of stroke that was linked not 
only to the degree of functional disability. This seminal study led to 
the development of a biological explanation for PSD, whereby brain 
changes would lead to depressive symptoms. This line of reasoning 
was primarily developed in the 1980’s by Robert Robinson’s group, 
from the University of Iowa, in opposition to the psychological 
perspective3,4. These opposing perspectives have led to many of the 
continuing controversies and uncertainties about emotional disorders 
following stroke.
Epidemiology
Since the first systematic studies, depression (major and minor) has 
been regarded as the most common neuropsychiatric disorder after 
stroke, with an estimated prevalence ranging from 18 to 60%3. Ac-
cording to DSM-V, MDD corresponds to the presence of at least four 
accessory symptoms, besides depressed mood or anhedonia. Minor 
Depressive Episode is a DMS-IV research diagnosis characterized 
by two to four depressive symptoms, including depressed mood or 
anhedonia6. DSM-V incorporated this syndrome into the category 
Other Specified Depressive Disorders: Depressive Episode with 
insufficient symptoms.
The prevalence of PSD among hospitalized patients in the acute 
phase is around 22% for major depression and 17% for minor depres-
sion. In outpatient samples (from 3 months to 10 years after stroke), 
it is around 23% for major depression and 35% for minor depression, 
while community samples exhibit mean prevalence rates of 13% and 
10%, respectively4. A recent meta-analysis showed that the prevalence 
of depression at any time after stroke was 29%7.
A cohort of 4,022 patients followed for 15 years showed the dy-
namic history of PSD8. The peak prevalence of MDD occurs 3 to 6 
months after the stroke. Most subjects had MDD remission one year 
after stroke, however showing persistent subsyndromal depressive 
symptoms and/or short lasting depressive episodes. Also according 
to Robinson, MDD often subside without complete remission one 
year after the index event4. 
In Brazil, there are few data on the epidemiology of PSD. A study 
conducted in Fortaleza, which investigated the quality of life (QoL) of 
individuals from two to six years post-stroke, reported a 40% preva-
lence of depressive symptoms (predominantly mild to moderate)9. 
The presence of depressive symptoms was the most important factor 
in reducing QoL. Similarly, de Souza et al. evaluated patients with 
Chagas disease and stroke, and found that QoL was more influenced 
by depressive symptoms than neurological disability10. Carod-Artal 
et al. also demonstrated that depression, disability and motor deficits 
were the main determinants of health-related QoL in patients with 
stroke, and depression was the strongest predictor of reduced QoL, 
especially among women11. Table 1 presents Brazilian studies that 
reported the frequency of PSD.
Diagnosis and clinical picture
The DSM-V criteria for the diagnosis of PSD match those for Depres-
sive Disorder Due to a Medical Condition6. Stroke is one of the few 
conditions listed in the former DSM-IV and the current DSM-V as 
“directly” causing depression; therefore PSD is diagnosed differently 
from depression following, for instance, a myocardial infarction or a 
hip fracture, and can be named as Depressive Disorder Due to Stroke. 
One of the following specifiers should be added to the diagnosis: 
“with depressive features”, if full criteria are not met for a major de-
pressive episode; “with major depressive-like episode”, if full criteria 
are met for a major depressive episode (except for criterion C); and 
“with mixed features”, if symptoms of mania or hypomania are also 
present but do not predominate in the clinical picture. 
Table 1. Frequency of post stroke depression in Brazilian studies
Author (year) City (state) n Setting Time after stroke Instrument
Frequency 
(%)
Simis, Nitrini 
(2006)12
Sorocaba 
(SP)
93 H 2 weeks HAM-D 59,1†
Carod-Artal  
et al. (2009)11
Brasília 
(DF)
260* O 20.7 
months 
(mean)
HADS 20,0†
(F: 25,0;  
M: 15,4)
Terroni et al. 
(2009)13
São Paulo 
(SP)
73 H/O 1 week – 4 
months
HAM-D 28,8‡
Fróes et al. 
(2011)9
Fortaleza 
(CE)
64 RP < 2 years: 
9.4%
2-6 years: 
50%
> 7 years: 
40.7%
BDI 40,0†
Scheffer et 
al. (2011)14
Porto 
Alegre 
(RS)
19* O 9 – 27 
months
BDI 33,3†
Rangel et al. 
(2013)15
Maceió 
(AL)
139* RP 3 – 316 
months
BDI 49,7†
BDI: Beck Depression Inventory; F: Female gender; H: Hospital sample; HADS: Hospital Anxiety 
and Depression Scale; HAM-D: Hamilton Depression Scale; M: Male gender; O: Outpatient 
sample; RP: Rehabilitation Program sample.
* The study included patients with hemorrhagic stroke (Ischemic stroke: Carod-Artal et al.: 87.7%, 
Scheffer et al. 84.2%; Rangel et al.: 83.5%).
† Prevalence; ‡ Incidence in 4 months.
PSD should be distinguished from post-stroke demoralization, 
which can be understood as a type of adjustment disorder. Several 
authors have attempted to differentiate depression and demoraliza-
tion16,17. This distinction may seem even more complicated when 
considering the concept of PSD adopted by the psychological 
perspective described above. Overall, demoralization is related 
to feelings of incompetence and loss of self-control after repeated 
failures, whereas depression is marked by anhedonia and decreased 
motivation. Shader observed that individuals with demoralization 
may respond favorably to positive stimuli and relief of stressors, 
while patients with depression cannot get rid of their negative mood 
state, regardless of environmental changes17. Once the presence of 
demoralization is recognized, the clinician should work with the 
patient in order to promote a sense of ability, mastery and return of 
hope. Encouragement, support and education are essential.
According to Spalletta and Robinson18, although it seems likely 
that some forms of PSD may be, in part, sustained by reaction to 
disability, the attempt to differentiate between “reactive” (i.e. de-
moralization) and “endogenous” forms of depression ceased many 
years ago because no clear etiopathogenetic or phenomenological 
distinction has ever been shown to distinguish between them and 
a mixture of these two forms is present in almost all patients with a 
diagnosis of depression. 
Fedoroff et al. assessed the suitability of the diagnostic criteria for 
MDD in the diagnosis of PSD19. They observed that, except for early-
morning awakening, all symptoms of depression were more frequent 
in the stroke patients with depressed mood than in the euthymic 
ones. Cumming et al. also conducted an investigation to determine 
whether the phenomenology of depression after stroke was differ-
ent from the phenomenology of depression with no known medical 
cause20. They noted that there were no major differences between the 
symptom profiles of both groups, except that stroke patients were less 
likely to report anhedonia than controls. Interestingly stroke patients 
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were no more likely than controls to report somatic complaints over 
psychological symptoms. However, some authors point to clinical dif-
ferences between patients with PSD and those with MDD. Compared 
to these, stroke patients would have more cognitive impairment, 
mood fluctuations, psychomotor retardation, anxiety and vegetative 
and somatic symptoms21. Gainotti et al. identified depressed mood, 
anhedonia and suicidal thoughts as more prevalent in non-stroke 
depressive patients than in patients with PSD21. In Brazil, Terroni 
et al. point out the relevance of fatigue symptoms and reduction of 
general interests in the diagnosis of PSD13. 
Despite these controversies, there is no evidence that the diag-
nosis of depression after stroke is less valid than the diagnosis of 
depression in non-stroke populations18,20. Since there are no specific 
biological markers, the diagnosis is based on clinical findings, and 
this task can become very difficult in the presence of severe cognitive 
deficits, especially language disorders.
Cognitive impairment in PSD
Cognitive deficits are commonly observed in depressed patients. Ex-
ecutive functions, including concept formation, planning, cognitive 
control, initiation and psychomotor speed, have been regularly shown 
to be impaired in depression22. Short term and working memory are 
disturbed in depression, as assessed either by the digit span test or by 
the digit ordering test. Objective memory deficit is regularly dem-
onstrated in depressed patients, characterized by lower immediate 
and delayed recall performance in both verbal and visual memory 
tests, but with a normal cued recall and recognition22. This pattern 
is typically described as a retrieval memory disorder, rather than a 
storage dysfunction. Language and visuospatial abilities are generally 
preserved in depression. 
A series of papers has specifically investigated cognitive disor-
ders in PSD. Post-stroke depression affects problem solving, verbal 
and visual memory, language, visuospatial processes, attention and 
psychomotor speed22,23. Moreover, the degree of cognitive impair-
ment is associated with the severity of depressive symptoms23.
In a cohort of 143 patients who were followed up to 10 months 
after a stroke, Nys et al. found that cognitive impairment at baseline 
independently predicted long-term depressive symptoms24. More-
Table 2. Key features of the biological and psychological hypothesis of post stroke depression (PSD) etiopathogenesis
Biological causation Psychological causation
Evidence Evidence
For Against For Against
Higher frequency of depression in stroke 
versus other similarly disabling medical 
illness
Temporal relationship between stroke 
and onset of depression
Specific lesions associated with PSD
PSD may occur in the context of silent 
infarcts
Finding not consistently replicated
Temporal relationship between 
psychological stressors (e.g. 
bereavement) and depression
Finding not consistently replicated
-
PSD symptom profile is not specific 
and may be a form of “functional” 
depression
Temporal relationship between 
psychological stressors (e.g. 
bereavement) and depression
Risk factors unrelated with stroke 
predicts occurrence of depression (e.g. 
family history of depression)
Disability severity is the most 
consistent risk factor for PSD 
and psychosocial factors become 
increasingly important in later onset 
PSD
“Functional” depression may have 
biological underpinnings
Temporal relationship between stroke 
and onset of depression
These risk factors may reflect biological 
predisposition (e.g. genetic causes)
-
Explanatory theories Explanatory theories
Lesion location theory: PSD may be related to the location of the lesions, disturbing 
specific areas of the brain (e.g. left frontal lobes, hippocampus, basal ganglia) 
Biogenic amines theory: PSD may be related to disruption of monoamines circuitry, 
through direct or indirect mechanisms 
Inflammatory cytokines theory: PSD may be related to the production of 
“depressogenic” cytokines by the inflammatory response to ischemia 
Genetic polymorphisms theory: PSD may be related to genetic predisposition, 
especially in the serotoninergic system
Patients with stroke experience a traumatic event that undermines their physical 
and mental integrity, their autonomy and self-esteem as well as their social 
lives. Psychological coping mechanisms, as well as premorbid personality, are 
responsible for the development of PSD
over, they found that cognitive deficits were related to worse quality 
of life. Among all cognitive deficits, the QoL was mostly affected by 
visuospatial and visuo-constructive disorders, while unilateral ne-
glect at baseline assessment was the greatest risk factor for depressive 
symptoms after 6 months. 
Taken together, these data suggest that cognitive deficits may 
account for PSD and, on the other hand, the degree of depression 
impacts on cognitive performance. Patients with PSD should undergo 
a formal neuropsychological evaluation, and therapeutic rehabilita-
tion program adapted according to the cognitive profile of the patient. 
Pathophysiology
The polarity between the biological and the psychological perspec-
tives may have hampered the development of a comprehensive ap-
proach to PSD prevention and treatment. Table 2 presents the main 
arguments of each school.
Among the major biological theories on the pathophysiology of 
PSD, four main hypotheses can be listed: lesion location, biogenic 
amines, inflammatory cytokines and gene polymorphism hypotheses. 
The lesion location hypothesis was formulated by Robinson 
based on the observation that depression severity was associated 
with lesions in the left frontal lobe, and that this association was 
stronger in the first 6 months after stroke4. However, this finding 
has not been consistently replicated by other authors. Carson et 
al., in a meta-analysis of 35 studies, observed that the risk for 
developing depression was not associated with lesion location25. 
Other authors proposed that strategic or specific location of the 
ischemic damage might play a role in the development of PSD26. 
Neuroimaging studies found the hippocampus, basal ganglia and 
frontal areas to be associated with PSD26. Although the debate is 
still open, the correlations between affected areas and depressive 
symptoms seem to be weak.
The biogenic amines theory can be understood as a pathophysi-
ological sophistication of the lesion location hypothesis. It was first 
proposed by Robinson and Bloom27. They postulated that ischemic 
lesions might interrupt the biogenic amine-containing axons 
ascending from the brainstem nuclei to the cerebral cortex, thus 
decreasing the release of serotonin (5-HT) and norepinephrine (NE) 
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in the limbic structures of the frontal and temporal lobes as well as in 
the basal ganglia. According to this hypothesis, lesions located in the 
anterior portions of the frontal lobes could interrupt the ascending 
monoaminergic axonal bundles leading to depression. Indeed, the 
studies of Robinson suggested that anterior lesions, located close 
to the left frontal pole, would be associated with the development 
of depressive symptoms4. Later it was suggested that dysfunction 
of cortico-striato-pallido-thalamic-cortical circuits predisposes to 
PSD, and that these loops could even be disrupted indirectly by 
secondary degeneration when not included in the primary isch-
emic lesion by means of anterograde or retrograde degeneration 
and vasogenic edema. This could explain, at least partly, the great 
variability described by anatomo-clinic correlational studies. In 
addition, it was observed that in acute brain lesion, there is de-
creased monoamine synthesis because of enzyme inhibition during 
ischemia. Accordingly, significantly lower cerebrospinal fluid (CSF) 
concentrations of the 5-HT metabolite 5-hydroxy-indoleacetic 
acid were measured in PSD patients compared to non-depressed 
stroke survivors28. Positron Emission Tomography (PET) findings 
on 5-HT1a receptor availability after stroke suggest that changes in 
5-HT neurotransmission may occur in the early phase of stroke and 
can be modulated by treatment with Selective Serotonin Reuptake 
Inhibitors (SSRIs)29.
Based on the strong association of proinflammatory cytokines, 
such as interkeukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), 
IL-6, IL-8 and IL-18, with ischemic brain injury and the evidence 
of interleukins playing an important role in certain subtypes of 
depression, Spalletta et al. proposed the inflammatory cytokines 
hypothesis for PSD30. In the last two decades, increased blood and 
CSF concentrations of pro-inflammatory cytokines, including IL-1β, 
IL-6, Interferon-γ (IFNγ) and TNFα, acute phase proteins, such as 
C-reactive protein (CRP), and their receptors, chemokines, adhesion 
molecules and other inflammatory mediators, have been demon-
strated in MDD subjects31. The long-term exposure to cytokines may 
be associated with the onset of depression. The best studied example 
comprises patients receiving IFN-α to treat melanoma and hepatitis 
C virus infection32. In experimental animals, the administration of 
cytokines, such as IL-6, or cytokine inducers, such as lipopolysaccha-
ride (LPS), have been found to induce depressive-like behaviors33. The 
inflammatory mediators seem to activate the widespread tryptophane 
catabolizing enzyme indoleamine 2,3-deoxygenase (IDO) leading 
to decreased synthesis of 5-HT. The importance of the activation of 
IDO in the pathophysiology of depression is also supported by the 
evidence that, in mice, the blockade of IDO inhibits the onset of the 
LPS-related “sickness behavior”33. Concerning PSD, experimental 
studies showed that, in mice, IL-1β and TNF-α can induce post-stroke 
depressive-like behavior resembling the somatic syndrome of depres-
sion in humans34. Regarding clinical studies, Jiménez et al. reported 
that serum leptin levels in patients with a first episode of ischemic 
stroke were associated with PSD at discharge from hospital and at one 
month after stroke35. Yang et al. observed that serum IL-18 measured 
7 days after hospital admission for stroke was associated with PSD 
in the acute stage and 6 months after stroke36. Recently, Spalletta et 
al. found that that serum IL-6 was increased in patients with depres-
sive disorders after stroke, and that its levels were associated with 
the severity of apathetic-amotivational and somatic symptoms of 
depression and of neurological deficits 72 hours after stroke37. There 
are many problems with this theory: several cytokines are involved 
in post-stroke inflammatory process, and they play different roles in 
distinct stages after stroke. Furthermore, many studies of cytokines 
are based on animals, and in patients, only the serum and CSF levels 
can be tested, while it is impossible to measure cytokines in specific 
areas of the living human brain. Besides that, molecular cascades 
after stroke also include a marked induction of anti-inflammatory 
cytokines, which may counterbalance the “depressiogenic” effect 
of proinflammatory cytokines. To examine the hypothesis, further 
researches are needed.
It has been proposed that MDD results from the interaction of 
predisposing genes and the environment. Nowadays, this relation-
ship emerges as the gene polymorphism hypothesis of PSD. Based 
on the theory of biogenic amines, the serotonergic system appears as 
a canor genetic susceptibility to PSD. Few studies have investigated 
the role of serotonin genes polymorphisms in PSD. For instance, 
Ramasubbu et al. reported that the Serotonin Transporter Gene-
Linked Promoter Region (5-HTTLPR) s allele was associated with 
PSD in a sample of 26 stroke patients with major depression and 
25 non-depressed stroke patients, the first genetic study of PSD38. 
Later, Kohen et al. replicated this finding with a larger sample of 75 
depressive and 75 non-depressive stroke patients categorized by the 
Geriatric Depression Scale39. Kim et al. found that 5-HTTLPR s/s 
genotype was associated with PSD40. Besides, they observed that Brain 
Derived Neurotrophic Factor (BDNF) met/met and 5-HT2a receptor 
(5-HTR2a) 1438 A/A genotypes were associated with PSD. On the 
other hand, Zhou et al. reported that serum BDNF concentrations 
were decreased in PSD patients 3 to 6 months after stroke, but this 
was not associated with BDNF gene Val66Met polymorphisms41. 
Tang et al. suggested a possible role for genetic variation in 5-HT2c 
receptors (HTR2C receptors) in the pathogenesis of PSD42. Based on 
the theory of inflammatory cytokines, Kim et al. reported that the 
IL-4 + 33C/C and the IL-10 –1082A/A genotypes were associated 
with PSD43. All these studies rely on very small samples and need to 
be replicated consistently in larger populations.
It should be noted that, traditionally, most studies on the patho-
physiology of PSD has focused on large vessel disease, without mak-
ing an explicit mention of lacunes26. However, paralleling this debate, 
the literature on “vascular depression” hypothesis is increasingly 
emphasizing the role of small vessel and microvascular chronic bur-
den in triggering depressive episodes26. According to this hypothesis, 
cerebrovascular disease could predispose, precipitate or perpetuate 
some geriatric depressive syndromes. Nevertheless, longitudinal 
studies in large community-based series of patients with PSD are 
needed to test the validity of this interesting proposal.
As the evidence supporting the different lines of biological ex-
planations has not pointed to definite conclusions, the psychological 
school still maintains proposals of psychosocial mechanisms for the 
pathogenesis of PSD. For instance, Gainotti et al. found that the symp-
tom profiles and anatomical–clinical correlates of major PSD were not 
different in the acute and more chronic stages21. He argued that this 
finding was more consistent with a psychological than a neurobiologi-
cal model of PSD. Lieberman et al. studied 516 hospitalized elderly 
patients, 221 after stroke and 295 after hip fracture44. There were no 
differences in the symptoms of depression score between the two 
groups, contradicting the influential work of Folstein et al.5. Bozikas 
et al. performed a clinicopathological analysis of 95 consecutively 
autopsied elderly individuals who survived an initial stroke and were 
followed to record the occurrence of PSD45. They observed that the 
severity of brain vessel arteriosclerosis and the frequency of brain 
vascular lesions were not significantly different between 21 cases with 
PSD and 74 cases without depression. No lesion pattern characterized 
the depression group. Thus, they suggested that psychological rather 
than neuropathological factors were the main determinants of PSD. 
In fact, patients who had a stroke experience a traumatic event that 
undermines their physical and mental integrity, their autonomy and 
self-esteem as well as their marital and professional lives21. Psychologi-
cal coping mechanisms, as well as premorbid personality, certainly 
play an important role in the development of PSD. However, these 
arguments are not sufficient to explain the emergence of depression 
after silent infarctions or in patients with anosognosia.
Ultimately, this polarity of thought appears unreasonable given 
the current understanding on the inseparable nature of somatic and 
psychiatric illness. PSD does not appear to be the result of “pure” 
biological versus psychological causes, but instead is multifactorial 
in origin and consistent with the biopsychosocial model of mental 
illness. At this time, more investigations are needed to clarify the rela-
tive contributions of both biological and psychosocial risk factors and 
their interactions to the development of poststroke psychopathology. 
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Many factors have been roughly associated with PSD46,47, as can 
be seen in figure 1, such as previous history of psychiatric disorders, 
female gender, family history of depression, and cerebrovascular risk 
factors, among others. Of those, physical disability, stroke severity 
and cognitive impairment have been more consistently associated 
with PSD48. Further, it has been suggested that patients who develop 
PSD just after a stroke have different risk factors than those who 
present a first episode later on49. Accordingly, early PSD would be 
closely related to biological mechanisms, whereas PSD developed six 
months after a stroke would be related to psychosocial mechanisms. 
A better understanding of the influence of these risk factors on the 
course of PSD and treatment response will lead to better treatment 
and, possibly, primary prevention interventions.
Treatment
There is consensus that, if PSD is left untreated, it may exert nega-
tive impact on functional recovery4. Longitudinal studies show that 
major and minor depressions are determinants of disability, failure 
in returning to work, impairment in interpersonal functioning and 
mortality4. 
The relation between PSD and functional impairment is com-
plex. Patients with PSD have significantly higher disability in ADLs 
than euthymic patients with comparable neurological deficits3. PSD 
negatively impacts on the involvement in rehabilitation programs and 
is associated with more institutional care and increase in using of 
health services3. These findings suggest a phenomenon of reciprocity, 
in which depression influences the recovery of ADLs and the impair-
ment of ADLs influences the severity and duration of depression. 
Increased mortality is perhaps the ultimate validation of the 
importance of depression in the prognosis following stroke. PSD 
appears to be a significant risk factor for increased death as early as 1 
year and as late as 7 years following stroke4. The mechanism underly-
ing increased death rates is an important issue, which has not been 
examined in depth. One study showed that PSD is associated with 
decreased heart rate variability (HRV)50. In this line, Tokgozoglu et al. 
reported that patients with decreased HRV, as a result of stroke lesions 
of the insular cortex, are at risk for sudden death51, and Makikallio et 
al. found that decreased long-term HRV was the only multivariate 
predictor of death after adjusting for age52.
There are no guidelines for PSD treatment and the effective-
ness of interventions is not well established. In a systematic review, 
Hackett et al. concluded that the use of antidepressants is associated 
with a small but significant beneficial effect53. According to the meta-
analysis conducted by Price et al., the use of antidepressants may be 
indicated on both major and minor depressive disorders, but there are 
no specific guidelines for the selection of drugs54. The most studied 
drugs were tricyclic antidepressants, especially nortriptyline, and 
SSRIs, particularly fluoxetine, sertraline and citalopram. There were 
also studies evaluating the use of trazodone, venlafaxine, reboxetine, 
mirtazapine, milnacipran and methylphenidate.
Some authors recommend the use of Nortriptyline as the first 
line drug, based on the evidence that it has a better efficacy than any 
other antidepressant available53. However, Nortriptyline may deter-
mine undesirable side effects and drug interactions, which can be 
problematic in a population at higher risk of cardiovascular disease. 
In this scenario, SSRIs are an interesting alternative. The use of an-
tidepressants in the prevention of PSD is even more controversial55. 
Isolated studies have shown benefits with nortriptyline, fluoxetine, 
sertraline, mirtazapine and methylphenidate. Nevertheless, a Co-
chrane systematic review found no significant effect of antidepressant 
use in the prevention of PSD55. 
One very interesting point is that antidepressants, especially 
SSRIs, have been associated with improvement of motor recovery 
and dependence after stroke even in patients without depression. 
Experimental studies reporting neurogenic and neuroprotective ef-
fects of SSRIs provide a plausible mechanism of action. The largest 
study conducted to date has been the “Fluoxetine in motor recovery 
of patients with acute ischaemic stroke” (FLAME) trial56. It was a 
double-blind, placebo-controlled trial, in which 118 ischemic stroke 
patients with moderate to severe motor deficits, without PSD, were 
randomly assigned to a 3-month treatment with Fluoxetine or pla-
cebo. The authors reported that, after 90 days, the early prescription 
of Fluoxetine with physiotherapy enhanced motor recovery. Besides, 
they noted that the early use of Fluoxetine prevented PSD. In a recent 
meta-analysis, 52 trials randomizing 4,059 patients to SSRI or control 
were assessed (28 used fluoxetine, 7 sertraline, 10 paroxetine, 5 cita-
lopram, 1 escitalopram, and 1 either sertraline or fluoxetine)57. The 
authors concluded that the favorable effects of SSRIs on disability, 
depressive symptoms, and neurological deficit scores were greater in 
participants who were depressed at randomization, but this may be 
due to quality bias. Besides, the authors report evidence of benefits 
of SSRIs in patients without depression, especially fluoxetine, the 
most studied drug. SSRIs appeared to improve dependence, disability, 
neurological impairment, anxiety and depression after stroke, despite 
the heterogeneity of the trials and several methodological limitations. 
Large, well-designed trials are needed to determine whether SSRIs 
should be routinely given to patients with stroke.
Figure 1. An integrative model of factors involved in post stroke depression pathogenesis. ADLs: activities of daily living.
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Although it has not been used in a randomized controlled trial, 
electroconvulsive therapy has also been reported to be effective in 
treating PSD4. Another emerging technique for the treatment of 
PSD is non invasive brain stimulation, which encompasses two 
main techniques: repetitive transcranial magnetic stimulation 
(rTMS) and transcranial direct current stimulation (tDCS). TMS 
depolarizes neurons using potent, focal electromagnetic fields that 
are generated beneath the coil positioned over the patient’s head. 
The electric depolarization, thereafter, induces action potentials. 
When applied repetitively and for several days, rTMS is able to 
induce clinical effects in several psychiatric disorders and is already 
used as a clinical (non-experimental) treatment in several coun-
tries, including Brazil. tDCS, in turn, is based on the application 
of a weak (0.5-2mA), direct electric current in the brain using 
electrodes placed over the head. Clinical effects are observed in 
several psychiatric disorders when applied daily for several days. 
These techniques might be particularly suitable for PSD as their side 
effects are limited to discomfort over the local of the application of 
the electrode/coil – i.e., they can induce depression improvement 
without systemic side effects. 
Despite the emerging evidence of these techniques, they are 
relatively poorly investigated in the context of major depression 
secondary to clinical disorders, including PSD. For instance, there 
are only two randomized, double-blinded clinical trials evaluat-
ing the efficacy of rTMS in PSD, studying 18 and 20 patients58,59. 
Both studies applied high-frequency (stimulatory) rTMS over 
the left dorsolateral prefrontal cortex, observing improvement 
of depressive symptoms. For tDCS, there is only one case report 
describing a patient with PSD, who showed marked improvement 
of symptoms after a 10-day course of tDCS60. In this context, there 
is one ongoing large double-blinded, randomized clinical trial 
enrolling 48 patients with PSD in the University of São Paulo, 
Brazil, which will provide more evidence regarding the use of 
tDCS for PSD treatment. This trial is registered at clinicaltrials.
gov (NCT01525524).
Finally, psychological treatment in isolation has been found to 
be no more effective than placebo. Psychotherapeutic approach as-
sociated with antidepressant use appears to be of some benefit. In 
the meta-analysis of Hackett et al., a small but significant effect was 
found for psychotherapy in preventing PSD55.
Conclusion
A narrative review of the literature was conducted to present a 
comprehensive panorama on PSD. It should be noted that, due the 
extent of the addressed theme, we opted to perform a non-systematic 
search. This method, however, imposes limitations associated with 
its non-quantitative nature. On the other hand, it was possible to 
describe in a detailed manner several aspects associated with this 
complication of stroke. 
As discussed above, depression is the most frequent psychiatric 
complication of cerebrovascular disorder. It is clear that it influences 
prognosis and functional recovery and its approach must be guar-
anteed for every stroke patient. Despite its great clinical relevance, 
there is little insight into its underlying etiological mechanisms and 
treament. For this reason, research addressed to elucidate the patho-
physiological mechanisms of PSD are important. In Brazil, despite the 
great impact of cerebrovascular diseases, data are scarce even for the 
implications of PSD, indicating the need for epidemiological surveys 
to characterize the population affected by poststroke neuropsychiatric 
syndromes in the country. 
A multidimensional approach taking into account biological, 
psychological and social perspectives is currently the most reasonable 
to the understanding of depressive symptoms following stroke, and 
to foster the development of evidence-based therapeutic strategies.
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